SynthesisClinical lymphoma & myeloma2009
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
Synthesis in Clinical lymphoma & myeloma, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Trial
- Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.Leukemia & lymphoma · 2013Trial
- Andrographolide inhibits Burkitt's lymphoma by binding JUN and CASP3 proteins.Cancer chemotherapy and pharmacology · 2024Article
- Pathohistological Diagnosis of Burkitt's Lymphoma After Cervical Biopsy-Case Report with Literature Review.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024Review
- Blinatumomab in Relapsed/Refractory Burkitt Lymphoma.Cancers · 2022Article
- Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report.World journal of gastroenterology · 2021Article
- Be mindful of the central nervous system in Burkitt lymphoma.Haematologica · 2021Article
- The balancing act in Burkitt lymphoma.Blood · 2021Article
- Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013.International journal of cancer · 2017Article
- Treating Burkitt Lymphoma in Adults.Current hematologic malignancy reports · 2015Review
- Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.Cancer research and treatment · 2015Article
- Burkittts lymphoma revisited: series of three cases with varied clinical presentation.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2014Article
- Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project.Journal of the National Cancer Institute. Monographs · 2014Article
- Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers.Therapeutic advances in hematology · 2014Review
- Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience.Current hematologic malignancy reports · 2013Review
- The role of hematopoietic SCT in adult Burkitt lymphoma.Bone marrow transplantation · 2013Review
- Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Article
- Pediatric, elderly, and emerging adult-onset peaks in Burkitt's lymphoma incidence diagnosed in four continents, excluding Africa.American journal of hematology · 2012Article
- Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma.Advances in hematology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 6 countries.
Funding
Abstract
Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens. The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years. Older patients have historically been underrepresented in published clinical trials of modern intensive therapy, and the outcome of these patients has not been systematically reported. We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature. Historically inferior outcomes of this age subgroup have improved substantially over time. We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma; (2) selected patients > age 40 now have highly favorable outcomes; and (3) future studies should include formal analysis of this subgroup of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.